Clinical trials: Inflammatory Bowel Diseases (IBD)
Ulcerative Colitis
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14…
- Trial name
- NCT00457171
- Testing
- GI-270384
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Inflammatory Bowel Diseases, Chronic Pain
Somatosensory Profiles in Individuals With Persistent Musculoskeletal Pain and Inflammatory Bowel Disease
This study evaluates nervous system hypersensitivity in individuals with inflammatory bowel disease (IBD) and experiences of ongoing musculoskeletal (MSK) pain.
- Conditions
- Inflammatory Bowel Diseases, Chronic Pain, Central Sensitization
- Trial name
- NCT03799471
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Crohn Disease
Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease
This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study examines subcutaneous dose of PF-06480605 150 mg administered every 4 weeks in participants with moderate to severe active Crohn's Disease to…
- Trial name
- NCT05471492
- Testing
- Investigational Product
- Sponsor
- Telavant, Inc.
Colon Neoplasms, Crohn Disease (CD)
Feasibility Study of the SEGER Device in Laparoscopic Gastrointestinal Surgery
This is a first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.
- Conditions
- Colon Neoplasms, Crohn Disease (CD), Obesity & Overweight
- Trial name
- SEGER-FIH (NCT07508592)
- Testing
- SEGER Device
- Where
- El Salvador
- Volunteers
- 10 people
- Sponsor
- Seger Surgical Solutions
Ileostomy - Stoma, Inflammatory Bowel Diseases
Stoma Closure and Reinforcement Trial ll
Hernia formation at sites of ostomy closure is a common complication. The investigator believes that using evidence based hernia repair techniques as a preventive measure during closure of ostomies will reduce the incidence of…
- Trial name
- SCAR-ll (NCT04916067)
- Testing
- Mesh Implantation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Ulcerative Colitis
Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
Inflammatory bowel disease is a group of chronic, non-specific inflammatory diseases of the intestinal tract whose etiology has not yet been fully elucidated, including ulcerative colitis and Crohn's disease.
- Trial name
- NCT05481619
- Testing
- Vedolizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Crohn's Disease
A Study To Monitor Long-Term Treatment With PF-00547659
This study provides open-label drug to eligible patients who have completed a prior study of PF-00547659. The primary endpoint for this study is long-term safety.
- Trial name
- OPERA II (NCT01298492)
- Testing
- PF-00547659
- Where
- 112 sites in United States, Austria and 13 more
- Volunteers
- 268 people
- Sponsor
- Shire
Crohn's Disease
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently…
- Trial name
- NCT00055536
- Testing
- natalizumab
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Ulcerative Colitis, Crohn's Disease
Multimodal Approach in IBD Patients
The investigators intend to assess the role of several biomarkers in the prediction of relapse in IBD. Clinical, laboratory and endoscopic data will be gathered and a predictive score will be derived in order to assess the…
- Conditions
- Ulcerative Colitis, Crohn's Disease, Nonalcoholic Fatty Liver Disease (NAFLD), Vitamin D Deficiency
- Trial name
- MAID (NCT01705522)
- Where
- Romania
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Colentina
Ulcerative Colitis
Dynamic Changes of Gut Microbiota in UC After FMT
A prospective study to investigate the dynamic changes of gut microbiota through colonic transendoscopic enteral tubing in patients with ulcerative colitis after fecal microbiota transplantation.
- Trial name
- NCT03949257
- Testing
- colonic transendoscopic enteral tubing
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Inflammatory Bowel Diseases
Multimodal Ultrasound in Inflammatory Bowel Diseases
The role of intestinal ultrasound in treatment monitoring has recently gained increasing interest thanks to its non-invasiveness, cost-effectiveness and largely availability.
- Trial name
- CELESTIAL (NCT05987501)
- Testing
- Multimodal ultrasound
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Crohn Disease, Colitis, Ulcerative
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
The purpose of this study is to assess the effectiveness of ustekinumab on extra-intestinal manifestations (EIMs) and immune-mediated inflammatory diseases (IMIDs) associated with inflammatory bowel disease (IBD) (both Crohn's…
- Trial name
- TENOR (NCT03606499)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Janssen Cilag S.A.S.
Ulcerative Colitis
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.
- Trial name
- PACE (NCT02093663)
- Testing
- MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Shire
Ulcerative Colitis
Methods of Improvement Adherence With Therapy in Ulcerative Colitis.
Ulcerative Colitis is associated with a significantly increased risk of colorectal cancer. This risk can be reduced through regular medication with 5ASA compounds.
- Trial name
- NCT00398593
- Testing
- Range of electronic pill dispensers with alarms
- Volunteers
- 80 people
- Sponsor
- University Hospitals, Leicester
Crohn Disease
A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China
Bio-naive participants are defined as the participants who previously have not received any biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the endoscopic remission at week 24 among…
- Trial name
- NCT06082986
- Testing
- Ustekinumab
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Crohn's Disease
Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
This study aims to determine which of 3 doses of a non-absorbable antibiotic Rifaximin is most effective in treating active moderate Crohn's disease.
- Trial name
- NCT00528073
- Testing
- Rifaximin-EIR
- Where
- 57 sites in France, Germany and 5 more
- Volunteers
- 410 people
- Sponsor
- Alfasigma S.p.A.
Pyoderma Gangrenosum, Crohn's Disease
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication.
- Conditions
- Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT00791557
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University Hospitals Cleveland Medical Center
Ulcerative Colitis
Beneficial Effect of Silymarin in Ulcerative Colitis
The goal of this clinical trial is to evaluate the possible beneficial effect of silymarin in Ulcerative Colitis adult patients receiving mesalamine.
- Trial name
- NCT06213857
- Testing
- Silymarin, Mesalamine, Azathioprine
- Where
- 2 sites in Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Crohn's Disease
Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
To compare treatment outcome in patients with Crohn's disease with secondary loss of response to infliximab (i.e. initial good response follow by loss of response) treated according to current standards based only on clinical…
- Trial name
- NCT00851565
- Testing
- Measurement of serum infliximab and anti-infliximab antibodies, Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status
- Where
- 8 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- Copenhagen University Hospital at Herlev
Crohn Disease
Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease
Some studies have shown that rifaximin is effective in the management of Crohn's Disease. Meanwhile, its adverse effect is tolerable. But no study has been conducted to assess its effect on preventing postoperative recurrence.
- Trial name
- NCT03185611
- Testing
- Rifaximin, Azathioprine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.